Scarica l'app Stockscreener
78.67
2.17%
1.67
Dopo l'orario di chiusura:
78.58
-0.09
-0.11%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NFLX Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$77.00
Aprire:
$76.61
Volume 24 ore:
30.86M
Relative Volume:
0.68
Capitalizzazione di mercato:
$332.16B
Reddito:
$45.27B
Utile/perdita netta:
$10.98B
Rapporto P/E:
31.13
EPS:
2.5272
Flusso di cassa netto:
$9.46B
1 W Prestazione:
+2.34%
1M Prestazione:
-9.84%
6M Prestazione:
-35.19%
1 anno Prestazione:
-23.21%
Intervallo 1D:
$76.40
$78.85
Intervallo di 1 settimana:
$75.30
$78.85
Portata 52W:
$75.23
$134.12
Netflix Inc Stock (NFLX) Company Profile
Nome
Netflix Inc
Settore
Industria
Telefono
408-540-3700
Indirizzo
121 ALBRIGHT WAY, LOS GATOS
Compare NFLX vs DIS, WBD, LYV, FOXA
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NFLX
Netflix Inc
|
78.67 | 325.11B | 45.27B | 10.98B | 9.46B | 2.5272 |
|
DIS
Walt Disney Co
|
105.58 | 187.78B | 95.62B | 13.27B | 7.06B | 6.7872 |
|
WBD
Warner Bros Discovery Inc
|
28.75 | 70.74B | 37.87B | 356.00M | 4.13B | 0.1876 |
|
LYV
Live Nation Entertainment Inc
|
162.67 | 36.56B | 24.57B | 532.09M | 1.59B | 1.37 |
|
FOXA
Fox Corporation
|
57.02 | 23.89B | 16.47B | 2.07B | 2.67B | 4.4433 |
Netflix Inc Stock (NFLX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-01-23 | Reiterato | Robert W. Baird | Outperform |
| 2026-01-21 | Reiterato | BMO Capital Markets | Outperform |
| 2026-01-21 | Reiterato | Canaccord Genuity | Buy |
| 2026-01-21 | Reiterato | Deutsche Bank | Hold |
| 2026-01-21 | Reiterato | Goldman | Neutral |
| 2026-01-21 | Reiterato | Guggenheim | Buy |
| 2026-01-21 | Reiterato | KeyBanc Capital Markets | Overweight |
| 2026-01-21 | Reiterato | Morgan Stanley | Overweight |
| 2026-01-21 | Reiterato | Needham | Buy |
| 2026-01-21 | Reiterato | Oppenheimer | Outperform |
| 2026-01-21 | Reiterato | Piper Sandler | Overweight |
| 2026-01-21 | Reiterato | Pivotal Research Group | Hold |
| 2026-01-21 | Reiterato | Rosenblatt | Neutral |
| 2026-01-21 | Reiterato | Rothschild & Co Redburn | Buy |
| 2026-01-21 | Reiterato | TD Cowen | Buy |
| 2026-01-21 | Reiterato | UBS | Buy |
| 2026-01-21 | Reiterato | Wolfe Research | Outperform |
| 2026-01-12 | Iniziato | HSBC Securities | Buy |
| 2026-01-09 | Reiterato | Goldman | Neutral |
| 2025-12-08 | Downgrade | Pivotal Research Group | Buy → Hold |
| 2025-12-08 | Downgrade | Rosenblatt | Buy → Neutral |
| 2025-11-18 | Reiterato | Barclays | Equal Weight |
| 2025-10-31 | Downgrade | Erste Group | Buy → Hold |
| 2025-10-07 | Aggiornamento | Seaport Research Partners | Neutral → Buy |
| 2025-09-17 | Aggiornamento | Loop Capital | Hold → Buy |
| 2025-07-10 | Reiterato | KeyBanc Capital Markets | Overweight |
| 2025-07-07 | Downgrade | Seaport Research Partners | Buy → Neutral |
| 2025-07-02 | Reiterato | Canaccord Genuity | Buy |
| 2025-07-02 | Reiterato | Goldman | Neutral |
| 2025-06-20 | Reiterato | Pivotal Research Group | Buy |
| 2025-06-12 | Reiterato | Oppenheimer | Outperform |
| 2025-06-03 | Reiterato | Jefferies | Buy |
| 2025-05-30 | Reiterato | BofA Securities | Buy |
| 2025-05-19 | Downgrade | JP Morgan | Overweight → Neutral |
| 2025-04-21 | Reiterato | BMO Capital Markets | Outperform |
| 2025-04-21 | Reiterato | Barclays | Equal Weight |
| 2025-04-21 | Reiterato | Canaccord Genuity | Buy |
| 2025-04-21 | Reiterato | Guggenheim | Buy |
| 2025-04-21 | Reiterato | JP Morgan | Overweight |
| 2025-04-21 | Reiterato | KeyBanc Capital Markets | Overweight |
| 2025-04-21 | Reiterato | MoffettNathanson | Buy |
| 2025-04-21 | Reiterato | Morgan Stanley | Overweight |
| 2025-04-21 | Reiterato | Oppenheimer | Outperform |
| 2025-04-21 | Reiterato | Piper Sandler | Overweight |
| 2025-04-21 | Reiterato | Pivotal Research Group | Buy |
| 2025-04-21 | Reiterato | Wells Fargo | Overweight |
| 2025-04-17 | Ripresa | Piper Sandler | Overweight |
| 2025-03-27 | Iniziato | FBN Securities | Outperform |
| 2025-03-17 | Aggiornamento | MoffettNathanson | Neutral → Buy |
| 2025-01-24 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2025-01-23 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2025-01-22 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2025-01-22 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2025-01-22 | Reiterato | Oppenheimer | Outperform |
| 2025-01-22 | Reiterato | Pivotal Research Group | Buy |
| 2025-01-22 | Aggiornamento | Rosenblatt | Neutral → Buy |
| 2025-01-22 | Aggiornamento | The Benchmark Company | Sell → Hold |
| 2025-01-16 | Aggiornamento | Seaport Research Partners | Neutral → Buy |
| 2025-01-15 | Reiterato | BMO Capital Markets | Outperform |
| 2025-01-15 | Reiterato | Oppenheimer | Outperform |
| 2025-01-08 | Reiterato | Goldman | Neutral |
| 2025-01-06 | Reiterato | Argus | Buy |
| 2025-01-03 | Reiterato | The Benchmark Company | Sell |
| 2024-12-19 | Reiterato | UBS | Buy |
| 2024-12-16 | Downgrade | Loop Capital | Buy → Hold |
| 2024-12-16 | Reiterato | Oppenheimer | Outperform |
| 2024-12-11 | Reiterato | JP Morgan | Overweight |
| 2024-11-20 | Reiterato | Pivotal Research Group | Buy |
| 2024-10-18 | Reiterato | Needham | Buy |
| 2024-10-18 | Reiterato | Oppenheimer | Outperform |
| 2024-10-18 | Reiterato | Pivotal Research Group | Buy |
| 2024-10-16 | Reiterato | Loop Capital | Buy |
| 2024-10-11 | Reiterato | Guggenheim | Buy |
| 2024-10-10 | Reiterato | Morgan Stanley | Overweight |
| 2024-10-10 | Reiterato | Oppenheimer | Outperform |
| 2024-10-07 | Downgrade | Barclays | Equal Weight → Underweight |
| 2024-10-07 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2024-10-01 | Reiterato | KeyBanc Capital Markets | Overweight |
| 2024-09-05 | Iniziato | China Renaissance | Hold |
| 2024-08-30 | Reiterato | Pivotal Research Group | Buy |
| 2024-07-17 | Reiterato | Guggenheim | Buy |
| 2024-07-16 | Reiterato | The Benchmark Company | Sell |
| 2024-07-15 | Reiterato | BofA Securities | Buy |
| 2024-07-12 | Reiterato | JP Morgan | Overweight |
| 2024-07-10 | Reiterato | KeyBanc Capital Markets | Overweight |
| 2024-07-09 | Reiterato | TD Cowen | Buy |
| 2024-07-02 | Reiterato | Argus | Buy |
| 2024-05-28 | Reiterato | Evercore ISI | Outperform |
| 2024-04-19 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2024-04-19 | Aggiornamento | Needham | Hold → Buy |
| 2024-04-19 | Reiterato | Pivotal Research Group | Buy |
| 2024-04-15 | Reiterato | Deutsche Bank | Hold |
| 2024-04-12 | Reiterato | Morgan Stanley | Overweight |
| 2024-04-12 | Reiterato | Piper Sandler | Neutral |
| 2024-04-05 | Reiterato | Pivotal Research Group | Buy |
| 2024-03-25 | Reiterato | Citigroup | Neutral |
| 2024-03-12 | Reiterato | Jefferies | Buy |
| 2024-03-11 | Reiterato | Oppenheimer | Outperform |
| 2024-01-30 | Downgrade | Seaport Research Partners | Buy → Neutral |
| 2024-01-25 | Aggiornamento | DZ Bank | Hold → Buy |
| 2024-01-24 | Reiterato | BMO Capital Markets | Outperform |
| 2024-01-24 | Reiterato | BofA Securities | Buy |
| 2024-01-24 | Reiterato | Canaccord Genuity | Buy |
| 2024-01-24 | Reiterato | Evercore ISI | Outperform |
| 2024-01-24 | Reiterato | Goldman | Neutral |
| 2024-01-24 | Reiterato | Guggenheim | Buy |
| 2024-01-24 | Reiterato | JP Morgan | Overweight |
| 2024-01-24 | Reiterato | KeyBanc Capital Markets | Overweight |
| 2024-01-24 | Aggiornamento | Macquarie | Neutral → Outperform |
| 2024-01-24 | Reiterato | Morgan Stanley | Overweight |
| 2024-01-24 | Reiterato | Oppenheimer | Outperform |
| 2024-01-24 | Reiterato | Piper Sandler | Neutral |
| 2024-01-24 | Reiterato | Pivotal Research Group | Buy |
| 2024-01-24 | Reiterato | Redburn Atlantic | Buy |
| 2024-01-24 | Reiterato | Robert W. Baird | Outperform |
| 2024-01-24 | Reiterato | TD Cowen | Outperform |
| 2024-01-24 | Reiterato | UBS | Buy |
| 2024-01-24 | Reiterato | Wells Fargo | Overweight |
| 2023-09-18 | Reiterato | Evercore ISI | Outperform |
| 2023-08-25 | Aggiornamento | Loop Capital | Hold → Buy |
| 2023-07-24 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2023-07-17 | Reiterato | Deutsche Bank | Buy |
| 2023-07-13 | Reiterato | JP Morgan | Overweight |
| 2023-07-12 | Reiterato | UBS | Buy |
| 2023-07-05 | Aggiornamento | Goldman | Sell → Neutral |
| 2023-06-29 | Reiterato | Citigroup | Buy |
| 2023-06-28 | Reiterato | Oppenheimer | Outperform |
| 2023-06-13 | Reiterato | BofA Securities | Buy |
| 2023-06-13 | Reiterato | Guggenheim | Buy |
| 2023-04-19 | Reiterato | Deutsche Bank | Buy |
| 2023-04-19 | Reiterato | JP Morgan | Overweight |
| 2023-04-19 | Reiterato | Jefferies | Buy |
| 2023-04-19 | Reiterato | Piper Sandler | Neutral |
| 2023-04-19 | Reiterato | Pivotal Research Group | Buy |
| 2023-04-19 | Reiterato | Rosenblatt | Neutral |
| 2023-04-19 | Aggiornamento | UBS | Neutral → Buy |
| 2023-04-11 | Ripresa | Robert W. Baird | Neutral |
| 2023-01-23 | Reiterato | Argus | Buy |
| 2023-01-20 | Reiterato | Canaccord Genuity | Buy |
| 2023-01-20 | Reiterato | Deutsche Bank | Buy |
| 2023-01-20 | Reiterato | Evercore ISI | Outperform |
| 2023-01-20 | Reiterato | Goldman | Sell |
| 2023-01-20 | Reiterato | Guggenheim | Buy |
| 2023-01-20 | Reiterato | Jefferies | Buy |
| 2023-01-20 | Reiterato | MoffettNathanson | Market Perform |
| 2023-01-20 | Reiterato | Oppenheimer | Outperform |
| 2023-01-20 | Reiterato | Piper Sandler | Neutral |
| 2023-01-20 | Reiterato | Pivotal Research Group | Buy |
| 2023-01-20 | Reiterato | Robert W. Baird | Neutral |
| 2023-01-20 | Reiterato | The Benchmark Company | Sell |
| 2023-01-20 | Reiterato | Wedbush | Outperform |
| 2023-01-20 | Reiterato | Wolfe Research | Outperform |
| 2023-01-12 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-01-04 | Iniziato | New Street | Neutral |
| 2022-12-29 | Aggiornamento | CFRA | Sell → Buy |
| 2022-12-14 | Reiterato | Jefferies | Hold |
| 2022-12-09 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-06-14 | Downgrade | The Benchmark Company | Hold → Sell |
| 2022-06-10 | Downgrade | Goldman | Neutral → Sell |
| 2022-05-16 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2022-04-21 | Downgrade | DZ Bank | Buy → Hold |
| 2022-04-21 | Downgrade | Edward Jones | Buy → Hold |
| 2022-04-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| 2022-04-20 | Downgrade | BofA Securities | Buy → Underperform |
| 2022-04-20 | Downgrade | JP Morgan | Overweight → Neutral |
| 2022-04-20 | Aggiornamento | Needham | Underperform → Hold |
| 2022-04-20 | Downgrade | Oppenheimer | Outperform → Perform |
| 2022-04-20 | Downgrade | Piper Sandler | Overweight → Neutral |
| 2022-04-20 | Downgrade | Pivotal Research Group | Buy → Sell |
| 2022-04-20 | Downgrade | Stifel | Buy → Hold |
| 2022-04-20 | Downgrade | UBS | Buy → Neutral |
| 2022-04-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-04-19 | Iniziato | Rosenblatt | Neutral |
| 2022-03-09 | Aggiornamento | Wedbush | Underperform → Neutral |
| 2022-01-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2022-01-31 | Aggiornamento | Edward Jones | Hold → Buy |
| 2022-01-24 | Downgrade | Jefferies | Buy → Hold |
| 2022-01-21 | Reiterato | BMO Capital Markets | Outperform |
| 2022-01-21 | Reiterato | BofA Securities | Buy |
| 2022-01-21 | Reiterato | Canaccord Genuity | Buy |
| 2022-01-21 | Reiterato | Cowen | Outperform |
| 2022-01-21 | Reiterato | Deutsche Bank | Hold |
| 2022-01-21 | Reiterato | Goldman | Neutral |
| 2022-01-21 | Reiterato | Guggenheim | Buy |
| 2022-01-21 | Reiterato | JP Morgan | Overweight |
| 2022-01-21 | Reiterato | MoffettNathanson | Neutral |
| 2022-01-21 | Downgrade | Monness Crespi & Hardt | Buy → Neutral |
| 2022-01-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-01-21 | Reiterato | Oppenheimer | Outperform |
| 2022-01-21 | Reiterato | Piper Sandler | Overweight |
| 2022-01-21 | Reiterato | Pivotal Research Group | Buy |
| 2022-01-21 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2022-01-21 | Reiterato | Stifel | Buy |
| 2022-01-21 | Aggiornamento | The Benchmark Company | Sell → Hold |
| 2022-01-21 | Downgrade | Truist | Buy → Hold |
| 2022-01-21 | Reiterato | UBS | Buy |
| 2022-01-21 | Reiterato | Wolfe Research | Outperform |
| 2021-12-15 | Reiterato | The Benchmark Company | Sell |
| 2021-10-20 | Downgrade | Deutsche Bank | Buy → Hold |
| 2021-10-20 | Reiterato | Monness Crespi & Hardt | Buy |
| 2021-09-29 | Reiterato | The Benchmark Company | Sell |
| 2021-09-13 | Iniziato | Goldman | Neutral |
| 2021-09-08 | Reiterato | JP Morgan | Overweight |
| 2021-09-07 | Reiterato | Atlantic Equities | Overweight |
| 2021-07-21 | Reiterato | Credit Suisse | Outperform |
| 2021-07-21 | Reiterato | Deutsche Bank | Buy |
| 2021-07-21 | Reiterato | JP Morgan | Overweight |
| 2021-07-21 | Reiterato | KeyBanc Capital Markets | Overweight |
| 2021-07-21 | Reiterato | Stifel | Buy |
| 2021-06-25 | Aggiornamento | Credit Suisse | Neutral → Outperform |
| 2021-06-25 | Iniziato | Edward Jones | Hold |
| 2021-05-19 | Ripresa | Jefferies | Buy |
| 2021-04-21 | Ripresa | Oppenheimer | Outperform |
| 2021-04-21 | Reiterato | Pivotal Research Group | Buy |
| 2021-04-21 | Aggiornamento | Stifel | Hold → Buy |
| 2021-04-06 | Ripresa | Evercore ISI | Outperform |
| 2021-04-01 | Iniziato | Piper Sandler | Overweight |
| 2021-03-25 | Reiterato | The Benchmark Company | Sell |
| 2021-03-23 | Aggiornamento | Argus | Hold → Buy |
| 2021-01-21 | Aggiornamento | DZ Bank | Hold → Buy |
| 2021-01-20 | Reiterato | Monness Crespi & Hardt | Buy |
| 2021-01-20 | Reiterato | Pivotal Research Group | Buy |
| 2021-01-20 | Reiterato | The Benchmark Company | Sell |
| 2021-01-20 | Aggiornamento | UBS | Neutral → Buy |
| 2021-01-20 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2020-10-21 | Reiterato | BMO Capital Markets | Outperform |
| 2020-10-21 | Reiterato | Bernstein | Outperform |
| 2020-10-21 | Reiterato | Jefferies | Buy |
| 2020-10-21 | Reiterato | Morgan Stanley | Overweight |
| 2020-10-21 | Reiterato | Oppenheimer | Outperform |
| 2020-10-21 | Reiterato | Piper Sandler | Overweight |
| 2020-10-21 | Reiterato | Pivotal Research Group | Buy |
| 2020-10-21 | Reiterato | RBC Capital Mkts | Outperform |
| 2020-10-21 | Reiterato | The Benchmark Company | Sell |
| 2020-10-21 | Reiterato | Wedbush | Underperform |
| 2020-10-21 | Reiterato | Wells Fargo | Equal Weight |
| 2020-10-16 | Reiterato | Morgan Stanley | Overweight |
| 2020-10-15 | Reiterato | Canaccord Genuity | Buy |
| 2020-10-14 | Reiterato | Goldman | Buy |
| 2020-10-07 | Reiterato | Pivotal Research Group | Buy |
| 2020-09-28 | Reiterato | The Benchmark Company | Sell |
| 2020-09-15 | Iniziato | KeyBanc Capital Markets | Overweight |
| 2020-09-09 | Ripresa | Raymond James | Mkt Perform |
| 2020-09-04 | Reiterato | The Benchmark Company | Sell |
| 2020-07-29 | Reiterato | Loop Capital | Buy |
Mostra tutto
Netflix Inc Borsa (NFLX) Ultime notizie
Ted Sarandos Says James Cameron Is “Part of the Paramount Disinformation Campaign” on Warner Bros. Deal - The Hollywood Reporter
Netflix releases a posthumous interview with Eric Dane after his death from ALS - KSAT
James Cameron slams Warner Bros.-Netflix bid, favours Paramount. Here’s a breakdown of both deals - CBC
Paramount Gets Early Antitrust Nod From DOJ for Warner Bros. - Bloomberg
Netflix (NFLX) Rises Higher Than Market: Key Facts - Yahoo Finance Australia
Netflix Says James Cameron Has It Wrong on Warner Movie Plans - Bloomberg
Want to Win the Warner Bros. Discovery Takeover Battle? ‘Walk Away Now.’ - Barron's
From Strip Law to The Addams Family : What to Watch on Netflix - Netflix
Netflix stock climbs on Warner Bros bidding deadline — what traders are watching next - Bez Kabli
Pokémon Horizons: Season 3—Rising Hope Part 2 Coming to Netflix - Pokemon.com
Eric Dane Gives Final Advice to His Daughters in Netflix’s Posthumous Interview Series, ‘Famous Last Words’ - IMDb
Netflix Makes Its WBD Case: Business Sense? 02/20/2026 - MediaPost
Brianne Gardner's Top Picks: ATS Corp, NRG Energy & Netflix - BNN Bloomberg
Netflix's Laura Ingalls Wilder Little House on the Prairie Adaptation: Cast, Filming, News - IMDb
These Experts Think Netflix Will Be Fine Even If It Doesn't Get to Buy Warner Bros. - Investopedia
Netflix Nabs Mexican Stop-Motion Animated Feature ‘I Am Frankelda’ - IMDb
Netflix stock rises as Warner Bros bid fight hits Monday deadline and fresh antitrust twist - TechStock²
Paramount Clears A U.S. Antitrust Hurdle In Bid For Warner Bros. Discovery; Netflix Notes Rival Is “A Long Way” From Getting Regulatory Signoffs — Update - IMDb
Antony Starr's Netflix Thriller Series 'Breakers' Rounds Out Cast - IMDb
Netflix doesn't need the Warner Bros. deal, but its rivals might - Yahoo! Finance Canada
Meta Platforms vs. Netflix: Which Is the Better Growth Stock to Buy? - The Motley Fool
Eric Dane’s Final Interview Before Death Streams on Netflix as Late Actor Shares Last Words to His Daughters: ‘I Stumbled, but I Tried… Fight Until Your Last Breath’ - IMDb
Netflix drama, Christmas feature among multiple productions filming in region - DiscoverAirdrie
Here’s what Paramount would have to do for Netflix to walk away from its Warner Bros. deal - MarketWatch
'Anemone': Netflix Release Date Revealed for Daniel Day-Lewis' Comeback - IMDb
Mckenna Grace to play Daphne in 'Scooby-Doo' live-action series at Netflix. Read more below. - facebook.com
Netflix (NFLX) Analyst Rating Reiterated at Outperform by Wedbus - GuruFocus
James Cameron Raises Concerns Over Netflix's Warner Bros. Acquisition - Intellectia AI
James Cameron just made 3 arguments against Netflix buying Warner Bros. The last one has stakes for the entire world - Fast Company
Media Deals Value Surges to $250 Billion Last Year, Driven by Netflix-Warner Bros., Premium Content - Yahoo Finance
Warner Bros. Discovery Acquisition: Netflix, Paramount-Skydance and the Future of Streaming Consolidation - Syracuse University Today
Jupiter Asset Management Ltd. Has $128.30 Million Holdings in Netflix, Inc. $NFLX - MarketBeat
'China's Netflix' Looks For Stardom In New Theme Park Business - Benzinga
Netflix (NFLX) Stock: Why a Billionaire Just Bought 10 Million Shares at a 42% Discount - Blockonomi
Paramount beats Netflix to clearing anti-trust hurdle in Warner Bros. acquisition - Yahoo Finance
Where Was Bridgerton Filmed? Discover The Key Locations 2026 - The Glossary
A dash of ‘schmuck insurance’ could help Netflix win Warner Bros - Financial Times
‘Severance’ Producer Boards Sequel to Nigerian Netflix Hit ‘Black Book’ (Exclusive) - IMDb
James Cameron voices concerns over 'disastrous' Netflix-Warner Bros. deal in letter - Yahoo Finance
Noah Kahan headed to Netflix with documentary about rise from VT roots - Burlington Free Press
Why this $2.7-billion money manager is buying Netflix and selling Adobe - The Globe and Mail
Netflix (NFLX) Stock; Drops Marginally While Considering Higher Warner Bros. Bid - CoinCentral
Netflix Poised to Shore Up Bid in Heated Warner Bros Acquisition Race - StockInvest.us
James Cameron wrote a letter Sen. Mike Lee, chairman of the Senate antitrust subcommittee, saying a Netflix-Warner Bros deal would threaten movie theaters. Read more below. - facebook.com
James Cameron Sounds Alarm Over Netflix-Warner Bros. Deal, Backs Paramount - IMDb
Apple Just Took a Page Straight Out of the Netflix Playbook. Here's Why It Could Be a Brilliant Move - Yahoo Finance
‘A Friend, A Murderer’ Launches on Netflix on March 5, 2026 - About Netflix
She Bet on K-Pop. Netflix Got Its Biggest Movie Ever. - Bloomberg
Netflix has ample room to increase its offer in battle for Warner Bros, sources say - The Spokesman-Review
Netflix co-CEO says Warner deal to put more films in cinemas - The Business Times
‘Avatar’ Director James Cameron Calls Netflix-WBD Disastrous, Bats For Paramount Takeover - Stocktwits
Netflix Inc Azioni (NFLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.40%
0.77%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):